Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 for Negative Symptoms of Schizophrenia
NCT01738698Phase 3Terminated
- Sponsor
- Takeda
- Start
- Nov 2012
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lisdexamfetamine in schizophrenia, sponsored by Takeda. Started Nov 2012; status: terminated.
02
Drugs
lisdexamfetamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01738698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01738698.